Cellebrite DI (NASDAQ:CLBT) Cut to “Sell” at Wall Street Zen

Cellebrite DI (NASDAQ:CLBT) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

CLBT has been the topic of a number of other research reports. Needham & Company LLC lowered their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 12th. JPMorgan Chase & Co. increased their price target on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Bank of America boosted their price objective on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, Lake Street Capital upped their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.50.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $15.30 on Friday. The stock has a 50-day simple moving average of $15.61 and a 200 day simple moving average of $16.94. Cellebrite DI has a 52-week low of $11.76 and a 52-week high of $20.86. The company has a market cap of $3.82 billion, a PE ratio of 49.35, a PEG ratio of 2.33 and a beta of 1.30.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. During the same quarter in the previous year, the business posted $0.10 EPS. The business’s quarterly revenue was up 28.8% compared to the same quarter last year. On average, research analysts predict that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Trading of Cellebrite DI

Several hedge funds have recently added to or reduced their stakes in CLBT. Venturi Wealth Management LLC lifted its position in Cellebrite DI by 5.0% during the third quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock worth $272,000 after purchasing an additional 700 shares during the period. CWM LLC increased its holdings in Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its position in shares of Cellebrite DI by 81.0% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock valued at $34,000 after buying an additional 850 shares in the last quarter. Blue Trust Inc. lifted its holdings in shares of Cellebrite DI by 4.0% during the 3rd quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after acquiring an additional 898 shares during the period. Finally, SkyView Investment Advisors LLC lifted its holdings in shares of Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after acquiring an additional 970 shares during the period. 45.88% of the stock is owned by institutional investors and hedge funds.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.